Treatment for PAH with Connective Tissue Disease Shows Promise in 2 Studies, Both Enrolling
Reata Pharmaceuticals has enrolled the first patient in its Phase 3 CATALYST trial (NCT02657356), exploring the potential benefits of bardoxolone methyl in people with pulmonary arterial hypertension (PAH) linked to connective tissue disease. The trial is continuing to recruit participants. The company also reported that data from the ongoing Phase 2 LARIAT…